Complement Receptor 1 Is a Potential Extracerebral Factor Promoting α-Synuclein Pathology.

Area of Science:

• Neuroscience
• Immunology
• Biochemistry

Background:

• Parkinson's disease (PD) is characterized by pathological alpha-synuclein (α-Syn) aggregation in the central nervous system (CNS).
• Pathological α-Syn is also found in peripheral tissues and body fluids of PD patients, with evidence suggesting its transmission from the body to the brain.
• The factors driving peripheral α-Syn aggregation remain largely unknown.

Purpose of the Study:

• To investigate the role of peripheral factors in promoting α-Syn pathology.
• To identify potential therapeutic targets for synucleinopathies by examining extracerebral influences on α-Syn aggregation.

Main Methods:

• In vitro experiments using the transmembrane domain of complement receptor 1 (CR1-TM) to assess its effect on α-Syn phosphorylation and aggregation.
• In vivo studies involving intravenous injection of α-Syn fibrils in a mouse model.
• Co-administration of CR1-TM with α-Syn fibrils to evaluate its impact on induced pathology in the brain.

Main Results:

• CR1, a peripheral blood system component, was identified as a promoter of α-Syn pathology.
• CR1-TM exacerbated α-Syn phosphorylation and aggregation in vitro.
• Intravenous injection of α-Syn fibrils induced brain pathology, which was worsened by co-administered CR1-TM.

Conclusions:

• Extracerebral factors, specifically CR1, can drive the progression of α-Syn pathology.
• CR1 represents a potential therapeutic target for treating Parkinson's disease and other synucleinopathies.